IL158506A0 - Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active active principle - Google Patents

Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active active principle

Info

Publication number
IL158506A0
IL158506A0 IL15850602A IL15850602A IL158506A0 IL 158506 A0 IL158506 A0 IL 158506A0 IL 15850602 A IL15850602 A IL 15850602A IL 15850602 A IL15850602 A IL 15850602A IL 158506 A0 IL158506 A0 IL 158506A0
Authority
IL
Israel
Prior art keywords
biguanide
daily
oral pharmaceutical
pharmaceutical form
active
Prior art date
Application number
IL15850602A
Other languages
English (en)
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of IL158506A0 publication Critical patent/IL158506A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15850602A 2001-05-23 2002-05-23 Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active active principle IL158506A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0106854A FR2825023B1 (fr) 2001-05-23 2001-05-23 Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
PCT/FR2002/001745 WO2002094285A1 (fr) 2001-05-23 2002-05-23 Forme pharmaceutique orale antidiabetique 'une prise par jour' comprenant une biguanide et au moins un autre principe actif

Publications (1)

Publication Number Publication Date
IL158506A0 true IL158506A0 (en) 2004-05-12

Family

ID=8863626

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15850602A IL158506A0 (en) 2001-05-23 2002-05-23 Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active active principle
IL158506A IL158506A (en) 2001-05-23 2003-10-20 Pharmaceutical dosage form for oral administration once daily that combines metformin and at least one other anti-diabetic active ingredient

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158506A IL158506A (en) 2001-05-23 2003-10-20 Pharmaceutical dosage form for oral administration once daily that combines metformin and at least one other anti-diabetic active ingredient

Country Status (10)

Country Link
US (1) US20040219212A1 (xx)
EP (1) EP1389118B9 (xx)
JP (1) JP4515032B2 (xx)
CA (1) CA2447926C (xx)
DE (1) DE60232963D1 (xx)
ES (1) ES2329555T3 (xx)
FR (1) FR2825023B1 (xx)
IL (2) IL158506A0 (xx)
PT (1) PT1389118E (xx)
WO (1) WO2002094285A1 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
WO2002055009A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003061643A1 (es) * 2002-01-25 2003-07-31 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
ATE457166T1 (de) * 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
EP1772149A1 (en) * 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
EP1909771A1 (en) * 2005-08-02 2008-04-16 Miv Therapeutics Inc. Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
AU2006311601A1 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN102105140B (zh) * 2008-07-02 2013-10-23 巴斯夫欧洲公司 涂覆片剂的方法
EA029077B1 (ru) * 2010-03-09 2018-02-28 Алкермес Фарма Айэленд Лимитед Устойчивая к спирту фармацевтическая лекарственная форма
GR1007299B (el) * 2010-03-24 2011-06-06 Uni - Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Αβεε, Πρωτοτυπη αναβραζουσα φαρμακευτικη συνθεση υδροχλωρικης μετφορμινης με τη μορφη δισκιου
US20120095059A1 (en) * 2010-04-13 2012-04-19 Jorge Luis Rosado Compositions and Methods for Treating Type II Diabetes and Related Disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
KR102231554B1 (ko) * 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법
KR20200137035A (ko) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
JP2015512945A (ja) * 2012-04-13 2015-04-30 バナー ファーマキャップス，インコーポレイティド 錠剤と液体または半固体の充填剤とを含む軟質弾性カプセル、ならびにそれらの製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079509C (en) * 1991-10-01 2002-05-14 Shigeyuki Takada Prolonged release microparticle preparation and production of the same
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AU3357499A (en) * 1998-03-18 1999-10-11 Peter Schenk Stationary exercise bicycle simulator
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
EP0974356B1 (en) * 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
DE19860698A1 (de) * 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
BR0015294A (pt) * 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation

Also Published As

Publication number Publication date
PT1389118E (pt) 2009-10-21
US20040219212A1 (en) 2004-11-04
FR2825023A1 (fr) 2002-11-29
DE60232963D1 (de) 2009-08-27
JP4515032B2 (ja) 2010-07-28
IL158506A (en) 2012-10-31
WO2002094285A1 (fr) 2002-11-28
EP1389118B1 (fr) 2009-07-15
FR2825023B1 (fr) 2005-04-15
EP1389118A1 (fr) 2004-02-18
JP2004534768A (ja) 2004-11-18
EP1389118B9 (fr) 2009-11-18
CA2447926C (fr) 2010-04-20
ES2329555T3 (es) 2009-11-27
CA2447926A1 (fr) 2002-11-28

Similar Documents

Publication Publication Date Title
IL158506A0 (en) Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active active principle
IL157477A0 (en) Pharmaceutical salts comprising a pharmaceutically active substance and a sugar substitute
HUP0301868A3 (en) Pharmaceutical composition comprising a factor viia and a factor xiii
HUP0400566A3 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
IL213240A (en) Pharmacy composition containing poly-fluorescein conjugate
HK1047231B (zh) 含有曲馬朵的具緩釋作用的口服藥物形式
HUP0300642A3 (en) Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent
AU2753001A (en) A medicinal aerosol formulation
AU4519001A (en) A medicinal aerosol formulation
IL159886A0 (en) Oral antidiabetic agents
PT1200118E (pt) Formulação farmacêutica compreendendo melagatrano e seu pró-fármaco
IL161143A0 (en) A flash-melt pharmaceutical oral dosage composition
HUP0303860A3 (en) A pharmaceutical tablet having a high active ingredient
AU2623401A (en) A medicinal aerosol formulation
IL153678A0 (en) A pharmaceutical component comprising a human parathyroid hormone
EP1379228A4 (en) (Z) -STYRYLBENZYLSULPONES AND THEIR PHARMACEUTICAL APPLICATIONS
AU2003257102A8 (en) Pharmaceutical dosage form comprising a sulfite compound
IL157451A0 (en) Medicinal compositions comprising diclofenac and ornoprostil
AU2002339078A1 (en) Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
PL361189A1 (en) Antidiabetic compositions containing a biguanide and a sulfonamide
EP1292283A4 (en) MEDICAL AEROSOL FORMULATION
PL358791A1 (en) Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative
HUP0402383A3 (en) Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof
ZA200309512B (en) Crystalline form a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same.
IL160195A0 (en) Oral dosage form comprising a therapeutic agent and an adverse-effect agent